nach oben

Erschienen in:

26.11.2019 | Clinical

Current management of succinate dehydrogenase–deficient gastrointestinal stromal tumors

verfasst von: Pushpa Neppala, Sudeep Banerjee, Paul T. Fanta, Mayra Yerba, Kevin A. Porras, Adam M. Burgoyne, Jason K. Sicklick

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Gastrointestinal stromal tumors (GISTs) are increasingly recognized as having diverse biology. With the development of tyrosine kinase inhibitors molecularly matched to oncogenic KIT and PDGFRA mutations, GISTs have become a quintessential model for precision oncology. However, about 5–10% of GIST lack these driver mutations and are deficient in succinate dehydrogenase (SDH), an enzyme that converts succinate to fumarate. SDH deficiency leads to accumulation of succinate, an oncometabolite that promotes tumorigenesis. SDH-deficient GISTs are clinically unique in that they generally affect younger patients and are associated with GIST-paraganglioma hereditary syndrome, also known as Carney-Stratakis Syndrome. SDH-deficient GISTs are generally resistant to tyrosine-kinase inhibitors, the standard treatment for advanced or metastatic GIST. Thus, surgical resection is the mainstay of treatment for localized disease, but recurrence is common. Clinical trials are currently underway investigating systemic agents for treatment of advanced SDH-deficient GIST. However, further studies are warranted to improve our understanding of SDH-deficient GIST disease biology, natural history, surgical approaches, and novel therapeutics.

Ma, G. L., Murphy, J. D., Martinez, M. E., & Sicklick, J. K. (2015). Epidemiology of gastrointestinal stromal tumors in the era of histology codes: results of a population-based study. Cancer Epidemiol Biomarkers Prev, 24(1), 298–302. https://doi.org/10.1158/1055-9965.EPI-14-1002.CrossRefPubMed

Kindblomd, L.-G., Remotti, H. E., Aldenborn, F., & Meis-Kindblom, J. M. (1998). Gastrointestinal pacemaker cell tumor (GIPACT) gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. American Journal of Pathology, 152(5).

Miettinen, M., Monihan, J. M., Sarlomo-Rikala, M., Kovatich, A. J., Carr, N. J., Emory, T. S., et al. (1999). Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: clinicopathologic and immunohistochemical study of 26 cases. The American Journal of Surgical Pathology, 23(9), 1109.CrossRefPubMed

Miettinen, M., Sarlomo-Rikala, M., Sobin, L. H., & Lasota, J. (2000). Esophageal stromal tumors: a clinicopathologic, immunohistochemical, and molecular genetic study of 17 cases and comparison with esophageal leiomyomas and leiomyosarcomas. The American Journal of Surgical Pathology, 24(2), 211–222.CrossRefPubMed

Miettinen, M., Sobin, L. H., & Lasota, J. (2005). Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. The American Journal of Surgical Pathology, 29(1), 52–68. https://doi.org/10.1097/01.pas.0000146010.92933.de.CrossRefPubMed

Erlandson, R. A., Klimstra, D. S., & Woodruff, J. M. (2009). Subclassification of gastrointestinal stromal tumors based on evaluation by electron microscopy and immunohistochemistry. Ultrastructural Pathology, 20(4), 373–393. https://doi.org/10.3109/01913129609016340.CrossRef

Miettinen, M. (1988). Gastrointestinal stromal tumors. An immunohistochemical study of cellular differentiation. American Journal of Clinical Pathology, 89(5), 601–610.CrossRefPubMed

Miettinen, M., & Lasota, J. (2001). Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Archiv, 438(1), 1–12. https://doi.org/10.1007/s004280000338.CrossRefPubMed

Dematteo, R. P., Heinrick, M. C., El-Rifai, W.-e., & Demetri, G. (2002). Clinical management of gastrointestinal stromal tumors: before and after STI-571. Human Pathology, 33(5), 478–483. https://doi.org/10.1053/hupa.2002.124123.CrossRef

10.

Hirota, S., Isozaki, K., Moriyama, Y., Hashimoto, K., Nishida, T., Ishiguro, S., Kawano, K., Hanada, M., Kurata, A., Takeda, M., Muhammad Tunio, G., Matsuzawa, Y., Kanakura, Y., Shinomura, Y., & Kitamura, Y. (1998). Gain-of-function mutations of c-kit n human gastrointestinal stromal tumors. Science, 279(5350), 577–580. https://doi.org/10.1126/science.279.5350.577.CrossRefPubMed

11.

Heinrich, M. C., Corless, C. L., Duensing, A., McGreevey, L., Chen, C.-J., Joseph, N., Singer, S., Griffith, D. J., Haley, A., Town, A., Demetri, G. D., Fletcher, C. D., & Fletcher, J. A. (2003). PDGFRA activating mutations in gastrointestinal stromal tumors. Science, 299(5607), 708–710. https://doi.org/10.1126/science.1079666.CrossRefPubMed

12.

Shi, E., Chmielecki, J., Tang, C. M., Wang, K., Heinrich, M. C., Kang, G., Corless, C. L., Hong, D., Fero, K. E., Murphy, J. D., Fanta, P. T., Ali, S. M., de Siena, M., Burgoyne, A. M., Movva, S., Madlensky, L., Heestand, G. M., Trent, J. C., Kurzrock, R., Morosini, D., Ross, J. S., Harismendy, O., & Sicklick, J. K. (2016). FGFR1 and NTRK3 actionable alterations in “Wild-Type” gastrointestinal stromal tumors. Journal of Translational Medicine, 14(1), 339. https://doi.org/10.1186/s12967-016-1075-6.CrossRefPubMedPubMedCentral

13.

Corless, C. L., Barnett, C. M., & Heinrich, M. C. (2011). Gastrointestinal stromal tumours: origin and molecular oncology. Nature Reviews Cancer, 11(12), 865–878. https://doi.org/10.1038/nrc3143.CrossRefPubMed

14.

Agaram, N. P., Wong, G. C., Guo, T., Maki, R. G., Singer, S., Dematteo, R. P., Besmer, P., & Antonescu, C. R. (2008). Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer, 47(10), 853–859. https://doi.org/10.1002/gcc.20589.CrossRefPubMedPubMedCentral

15.

Brenca, M., Rossi, S., Polano, M., Gasparotto, D., Zanatta, L., Racanelli, D., Valori, L., Lamon, S., Dei Tos, A. P., & Maestro, R. (2016). Transcriptome sequencing identifies ETV6-NTRK3 as a gene fusion involved in GIST. Journal of Pathology, 238(4), 543–549. https://doi.org/10.1002/path.4677.CrossRef

16.

Miranda, C., Nucifora, M., Molinari, F., Conca, E., Anania, M. C., Bordoni, A., Saletti, P., Mazzucchelli, L., Pilotti, S., Pierotti, M. A., Tamborini, E., Greco, A., & Frattini, M. (2012). KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Clinical Cancer Research, 18(6), 1769–1776. https://doi.org/10.1158/1078-0432.CCR-11-2230.CrossRefPubMed

17.

Alkhuziem, M., Burgoyne, A. M., Fanta, P. T., Tang, C.-M., & Sicklick, J. K. (2017). The call of “The Wild”-type GIST: It’s time for domestication. Journal of the National Comprehensive Cancer Network, 15(5), 551–554. https://doi.org/10.6004/jnccn.2017.0057.CrossRefPubMedPubMedCentral

18.

Janeway, K. A., Kim, S. Y., Lodish, M., Nose, V., Rustin, P., Gaal, J., et al. (2011). Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proceedings of the National Academy of Sciences of the United States of America, 108(1), 314–318. https://doi.org/10.1073/pnas.1009199108.CrossRefPubMed

19.

Miettinen, M., Wang, Z. F., Sarlomo-Rikala, M., Osuch, C., Rutkowski, P., & Lasota, J. (2011). Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age. The American Journal of Surgical Pathology, 35(11), 1712–1721. https://doi.org/10.1097/PAS.0b013e3182260752.CrossRefPubMedPubMedCentral

20.

Pasini, B., McWhinney, S. R., Bei, T., Matyakhina, L., Stergiopoulos, S., Muchow, M., et al. (2008). Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. European Journal of Human Genetics, 16(1), 79–88. https://doi.org/10.1038/sj.ejhg.5201904.CrossRefPubMed

21.

Boikos, S. A., Pappo, A. S., Killian, J., et al. (2016). Molecular subtypes of KIT/PDGFRa wild-type gastrointestinal stromal tumors: a report from the National Institutes of Health gastrointestinal stromal tumor clinic. JAMA Oncology, 2(7), 922–928. https://doi.org/10.1001/jamaoncol.2016.0256.CrossRefPubMedPubMedCentral

22.

Mullassery, D., & Weldon, C. B. (2016). Pediatric/“Wildtype” gastrointestinal stromal tumors. Seminars in Pediatric Surgery, 25(5), 305–310. https://doi.org/10.1053/j.sempedsurg.2016.09.004.CrossRefPubMed

23.

Wang, Y. M., Gu, M. L., & Ji, F. (2015). Succinate dehydrogenase-deficient gastrointestinal stromal tumors. World Journal of Gastroenterology, 21(8), 2303–2314. https://doi.org/10.3748/wjg.v21.i8.2303.CrossRefPubMedPubMedCentral

24.

Miettinen, M., & Lasota, J. (2014). Succinate dehydrogenase deficient gastrointestinal stromal tumors (GISTs) - a review. The International Journal of Biochemistry & Cell Biology, 53, 514–519. https://doi.org/10.1016/j.biocel.2014.05.033.CrossRef

25.

Gottlieb, E., & Tomlinson, I. P. M. (2005). Mitochondrial tumour suppressors: a genetic and biochemical update. [Review Article]. Nature Reviews Cancer, 5, 857. https://doi.org/10.1038/nrc1737.CrossRefPubMed

26.

Rutter, J., Winge, D. R., & Schiffman, J. D. (2010). Succinate dehydrogenase - assembly, regulation and role in human disease. Mitochondrion, 10(4), 393–401. https://doi.org/10.1016/j.mito.2010.03.001.CrossRefPubMedPubMedCentral

27.

Lussey-Lepoutre, C., Hollinshead, K. E. R., Ludwig, C., Menara, M., Morin, A., Castro-Vega, L.-J., et al. (2015). Loss of succinate dehydrogenase activity results in dependency on pyruvate carboxylation for cellular anabolism. Nature communications, 6, 8784–8784. https://doi.org/10.1038/ncomms9784.CrossRefPubMed

28.

Cardaci, S., Zheng, L., MacKay, G., van den Broek, N. J. F., MacKenzie, E. D., Nixon, C., et al. (2015). Pyruvate carboxylation enables growth of SDH-deficient cells by supporting aspartate biosynthesis. Nature cell biology, 17(10), 1317–1326. https://doi.org/10.1038/ncb3233.CrossRefPubMedPubMedCentral

29.

Soderberg, K. L., Ditta, G. S., & Scheffler, I. E. (1977). Mammalian cells with defective mitochondrial functions: a Chinese hamster mutant cell line lacking succinate dehydrogenase activity. Cell, 10(4), 697–702. https://doi.org/10.1016/0092-8674(77)90103-9.CrossRefPubMed

30.

Baysal, B. E., Ferrell, R. E., Willett-Brozick, J. E., Lawrence, E. C., Myssiorek, D., Bosch, A., van der Mey, A., Taschner, P. E., Rubinstein, W. S., Myers, E. N., Richard 3rd, C. W., Cornelisse, C. J., Devilee, P., & Devlin, B. (2000). Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science, 287(5454), 848–851. https://doi.org/10.1126/science.287.5454.848.CrossRefPubMed

31.

Astuti, D., Latif, F., Dallol, A., Dahia, P. L., Douglas, F., George, E., Sköldberg, F., Husebye, E. S., Eng, C., & Maher, E. R. (2001). Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. American Journal of Human Genetics, 69(1), 49–54. https://doi.org/10.1086/321282.CrossRefPubMedPubMedCentral

32.

Bardella, C., Pollard, P. J., & Tomlinson, I. (2011). SDH mutations in cancer. Biochimica et Biophysica Acta, 1807(11), 1432–1443. https://doi.org/10.1016/j.bbabio.2011.07.003.CrossRefPubMed

33.

Burnichon, N., Vescovo, L., Amar, L., Libe, R., de Reynies, A., Venisse, A., et al. (2011). Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Human Molecular Genetics, 20(20), 3974–3985. https://doi.org/10.1093/hmg/ddr324.CrossRefPubMed

34.

Ricketts, C., Woodward, E. R., Killick, P., Morris, M. R., Astuti, D., Latif, F., & Maher, E. R. (2008). Germline SDHB mutations and familial renal cell carcinoma. Journal of the National Cancer Institute, 100(17), 1260–1262. https://doi.org/10.1093/jnci/djn254.CrossRefPubMed

35.

Iommarini, L., Porcelli, A. M., Gasparre, G., & Kurelac, I. (2017). Non-canonical mechanisms regulating hypoxia-inducible factor 1 alpha in cancer. Frontiers in Oncology, 7, 286. https://doi.org/10.3389/fonc.2017.00286.CrossRefPubMedPubMedCentral

36.

Fuhler, G. M., Eppinga, H., & Peppelenbosch, M. P. (2017). Fumarates and cancer. Trends in Molecular Medicine, 23(1), 3–5. https://doi.org/10.1016/j.molmed.2016.12.001.CrossRefPubMed

37.

Frezza, C., Pollard, P. J., & Gottlieb, E. (2011). Inborn and acquired metabolic defects in cancer. Journal of Molecular Medicine, 89(3), 213–220. https://doi.org/10.1007/s00109-011-0728-4.CrossRefPubMed

38.

Ruas, J. L., & Poellinger, L. (2005). Hypoxia-dependent activation of HIF into a transcriptional regulator. Seminars in Cell and Developmental Biology, 16(4-5), 514–522. https://doi.org/10.1016/j.semcdb.2005.04.001.CrossRefPubMed

39.

Selak, M. A., Armour, S. M., MacKenzie, E. D., Boulahbel, H., Watson, D. G., Mansfield, K. D., et al. (2005). Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell, 7. https://doi.org/10.1016/j.ccr.2004.11.022.CrossRefPubMed

40.

MacKenzie, E. D., Selak, M. A., Tennant, D. A., Payne, L. J., Crosby, S., Frederiksen, C. M., et al. (2007). Cell-permeating alpha-ketoglutarate derivatives alleviate pseudohypoxia in succinate dehydrogenase-deficient cells. Molecular and Cellular Biology, 27(9), 3282–3289. https://doi.org/10.1128/MCB.01927-06.CrossRefPubMedPubMedCentral

41.

Guerra, F., Guaragnella, N., Arbini, A. A., Bucci, C., Giannattasio, S., & Moro, L. (2017). Mitochondrial dysfunction: a novel potential driver of epithelial-to-mesenchymal transition in cancer. Frontiers in Oncology, 7, 295–295. https://doi.org/10.3389/fonc.2017.00295.CrossRefPubMedPubMedCentral

42.

Aspuria, P.-J. P., Lunt, S. Y., Väremo, L., Vergnes, L., Gozo, M., Beach, J. A., et al. (2014). Succinate dehydrogenase inhibition leads to epithelial-mesenchymal transition and reprogrammed carbon metabolism. Cancer & Metabolism, 2(1), 21. https://doi.org/10.1186/2049-3002-2-21.CrossRef

43.

Yang, L., Moss, T., Mangala, L. S., Marini, J., Zhao, H., Wahlig, S., Armaiz-Pena, G., Jiang, D., Achreja, A., Win, J., Roopaimoole, R., Rodriguez-Aguayo, C., Mercado-Uribe, I., Lopez-Berestein, G., Liu, J., Tsukamoto, T., Sood, A. K., Ram, P. T., & Nagrath, D. (2014). Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Molecular Systems Biology, 10(5), 728. https://doi.org/10.1002/msb.20134892.CrossRefPubMedPubMedCentral

44.

Loriot, C., Domingues, M., Berger, A., Menara, M., Ruel, M., Morin, A., et al. (2015). Deciphering the molecular basis of invasiveness in Sdhb-deficient cells. Oncotarget, 6(32), 32955–32965. https://doi.org/10.18632/oncotarget.5106.CrossRefPubMedPubMedCentral

45.

Røsland, G. V., Dyrstad, S. E., Tusubira, D., Helwa, R., Tan, T. Z., Lotsberg, M. L., Pettersen, I. K. N., Berg, A., Kindt, C., Hoel, F., Jacobsen, K., Arason, A. J., Engelsen, A. S. T., Ditzel, H. J., Lønning, P. E., Krakstad, C., Thiery, J. P., Lorens, J. B., Knappskog, S., & Tronstad, K. J. (2019). Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC. Cancer & Metabolism, 7, 6–6. https://doi.org/10.1186/s40170-019-0197-8.CrossRef

46.

Miettinen, M., Killian, J. K., Wang, Z. F., Lasota, J., Lau, C., Jones, L., Walker, R., Pineda, M., Zhu, Y. J., Kim, S. Y., Helman, L., & Meltzer, P. (2013). Immunohistochemical loss of succinate dehydrogenase subunit A (SDHA) in gastrointestinal stromal tumors (GISTs) signals SDHA germline mutation. The American Journal of Surgical Pathology, 37(2), 234–240. https://doi.org/10.1097/PAS.0b013e3182671178.CrossRefPubMedPubMedCentral

47.

Burnichon, N., Briere, J. J., Libe, R., Vescovo, L., Riviere, J., Tissier, F., et al. (2010). SDHA is a tumor suppressor gene causing paraganglioma. Human Molecular Genetics, 19(15), 3011–3020. https://doi.org/10.1093/hmg/ddq206.CrossRefPubMedPubMedCentral

48.

Pantaleo, M. A., Astolfi, A., Indio, V., Moore, R., Thiessen, N., Heinrich, M. C., Gnocchi, C., Santini, D., Catena, F., Formica, S., Martelli, P. L., Casadio, R., Pession, A., & Biasco, G. (2011). SDHA loss-of-function mutations in KIT-PDGFRA wild-type gastrointestinal stromal tumors identified by massively parallel sequencing. Journal of the National Cancer Institute, 103(12), 983–987. https://doi.org/10.1093/jnci/djr130.CrossRefPubMed

49.

Bannon, A. E., Kent, J. D., Forquer, I., Town, A., Klug, L. R., McCann, K. E., et al. (2017). Biochemical, molecular, and clinical characterization of succinate dehydrogenase subunit a variants of unknown significance. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-1397.CrossRefPubMedPubMedCentral

50.

Killian, J. K., Miettinen, M., Walker, R. L., Wang, Y., Zhu, Y. J., Waterfall, J. J., et al. (2014). Recurrent epimutation of SDHC in gastrointestinal stromal tumors. Science Translational Medicine, 6(268), 1–9. https://doi.org/10.1126/scitranslmed.3009961.CrossRef

51.

Carney, J. A., Sheps, S. G., Go, V. L. W., & Gordon, H. (1977). The triad of gastric leiomyosarcoma, functioning extra-adrenal paraganglioma and pulmonary chondroma. New England Journal of Medicine, 296(26), 1517–1518. https://doi.org/10.1056/nejm197706302962609.CrossRef

52.

Matyakhina, L., Bei, T. A., McWhinney, S. R., Pasini, B., Cameron, S., Gunawan, B., et al. (2007). Genetics of carney triad: recurrent losses at chromosome 1 but lack of germline mutations in genes associated with paragangliomas and gastrointestinal stromal tumors. The Journal of Clinical Endocrinology & Metabolism, 92(8), 2938–2943. https://doi.org/10.1210/jc.2007-0797.CrossRef

53.

Stratakis, C. A., & Carney, J. A. (2009). The triad of paragangliomas, gastric stromal tumours and pulmonary chondromas (Carney triad), and the dyad of paragangliomas and gastric stromal sarcomas (Carney-Stratakis syndrome): molecular genetics and clinical implications. Journal of Internal Medicine, 266(1), 43–52. https://doi.org/10.1111/j.1365-2796.2009.02110.x.CrossRefPubMedPubMedCentral

54.

Sicklick, J. K., & Lopez, N. E. (2013). Optimizing surgical and imatinib therapy for the treatment of gastrointestinal stromal tumors. Journal of Gastrointestinal Surgery, 17(11), 1997–2006. https://doi.org/10.1007/s11605-013-2243-0.CrossRefPubMedPubMedCentral

55.

Mei, L., Du, W., Idowu, M., von Mehren, M., & Boikos, S. A. (2018). Advances and challenges on management of gastrointestinal stromal tumors. Frontiers in Oncology, 8, 135. https://doi.org/10.3389/fonc.2018.00135.CrossRefPubMedPubMedCentral

56.

DeMatteo, R. P., Lewis, J. J., Leung, D., Mudan, S. S., Woodruff, J. M., & Brennan, M. F. (2000). Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Annals of Surgery, 231(1), 51–58.CrossRefPubMedPubMedCentral

57.

Janeway, K. A., Liegl, B., Harlow, A., Le, C., Perez-Atayde, A., Kozakewich, H., et al. (2007). Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. Cancer Research, 67(19), 9084–9088. https://doi.org/10.1158/0008-5472.CAN-07-1938.CrossRefPubMed

58.

Willobee, B. A., Quiroz, H. J., Sussman, M. S., Thorson, C. M., Sola, J. E., & Perez, E. A. (2018). Current treatment strategies in pediatric gastrointestinal stromal cell tumor. Translational Gastroenterology and Hepatology, 3, 53–53. https://doi.org/10.21037/tgh.2018.07.09.CrossRefPubMedPubMedCentral

59.

Fero, K. E., Coe, T. M., Fanta, P. T., Tang, C. M., Murphy, J. D., & Sicklick, J. K. (2017). Surgical management of adolescents and young adults with gastrointestinal stromal tumors: a US population-based analysis. JAMA Surgery, 152(5), 443–451. https://doi.org/10.1001/jamasurg.2016.5047.CrossRefPubMedPubMedCentral

60.

Weldon, C. B., Madenci, A. L., Boikos, S. A., Janeway, K. A., George, S., von Mehren, M., Pappo, A. S., Schiffman, J. D., Wright, J., Trent, J. C., Pacak, K., Stratakis, C. A., Helman, L. J., & la Quaglia, M. P. (2017). Surgical management of wild-type gastrointestinal stromal tumors: a report from the National Institutes of Health Pediatric and Wildtype GIST Clinic. Journal of Clinical Oncology, 35(5), 523–528. https://doi.org/10.1200/jco.2016.68.6733.CrossRefPubMed

61.

Norton, J. A., Kim, T., Kim, J., McCarter, M. D., Kelly, K. J., Wong, J., et al. (2018). SSAT state-of-the-art conference: current surgical management of gastric tumors. Journal of Gastrointestinal Surgery, 22(1), 32–42. https://doi.org/10.1007/s11605-017-3533-8.CrossRefPubMed

62.

Heinrich, M. C., Rankin, C., Blanke, C. D., Demetri, G. D., Borden, E. C., Ryan, C. W., von Mehren, M., Blackstein, M. E., Priebat, D. A., Tap, W. D., Maki, R. G., Corless, C. L., Fletcher, J. A., Owzar, K., Crowley, J. J., Benjamin, R. S., & Baker, L. H. (2017). Correlation of long-term results of imatinib in advanced gastrointestinal stromal tumors with next-generation sequencing results: analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncology, 3(7), 944–952. https://doi.org/10.1001/jamaoncol.2016.6728.CrossRefPubMedPubMedCentral

63.

Demetri, G. D., van Oosterom, A. T., Garrett, C. R., Blackstein, M. E., Shah, M. H., Verweij, J., et al. (2006). Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. The Lancet, 368(9544), 1329–1338. https://doi.org/10.1016/S0140-6736(06)69446-4.CrossRef

64.

Heinrich, M. C., Maki, R. G., Corless, C. L., Antonescu, C. R., Harlow, A., Griffith, D., Town, A., McKinley, A., Ou, W. B., Fletcher, J. A., Fletcher, C. D., Huang, X., Cohen, D. P., Baum, C. M., & Demetri, G. D. (2008). Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. Journal of Clinical Oncology, 26(33), 5352–5359. https://doi.org/10.1200/JCO.2007.15.7461.CrossRefPubMedPubMedCentral

65.

Ben-Ami, E., Barysauskas, C. M., Von Mehren, M., Heinrich, M. C., Corless, C. L., Butrynski, J. E., et al. (2016). Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy. Annals of Oncology, 27(9), 1794–1799. https://doi.org/10.1093/annonc/mdw228.CrossRefPubMedPubMedCentral

66.

Ganjoo, K. N., Villalobos, V. M., Kamaya, A., Fisher, G. A., Butrynski, J. E., Morgan, J. A., Wagner, A. J., D'Adamo, D., McMillan, A., Demetri, G. D., & George, S. (2014). A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib. Annals of Oncology, 25(1), 236–240. https://doi.org/10.1093/annonc/mdt484.CrossRefPubMedPubMedCentral

67.

Tsang, L. L. H., Quarterman, C. P., Gescher, A., & Slack, J. A. (1991). Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide. [journal article]. Cancer Chemotherapy and Pharmacology, 27(5), 342–346. https://doi.org/10.1007/bf00688855.CrossRefPubMed

68.

Trent, J. C., Beach, J., Burgess, M. A., Papadopolous, N., Chen, L. L., Benjamin, R. S., & Patel, S. R. (2003). A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer, 98(12), 2693–2699. https://doi.org/10.1002/cncr.11875.CrossRefPubMed

69.

Garcia Del Muro, X., Lopez-Pousa, A., Martin, J., Buesa, J. M., Martinez-Trufero, J., Casado, A., et al. (2005). A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma. Cancer, 104(8), 1706–1712. https://doi.org/10.1002/cncr.21384.CrossRefPubMed

70.

Hadoux, J., Favier, J., Scoazec, J. Y., Leboulleux, S., Al Ghuzlan, A., Caramella, C., et al. (2014). SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. International Journal of Cancer, 135(11), 2711–2720. https://doi.org/10.1002/ijc.28913.CrossRefPubMed

71.

Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., Rubinstein, L., Shankar, L., Dodd, L., Kaplan, R., Lacombe, D., & Verweij, J. (2009). New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal of Cancer, 45(2), 228–247. https://doi.org/10.1016/j.ejca.2008.10.026.CrossRefPubMed

72.

Letouze, E., Martinelli, C., Loriot, C., Burnichon, N., Abermil, N., Ottolenghi, C., et al. (2013). SDH mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell, 23. https://doi.org/10.1016/j.ccr.2013.04.018.CrossRefPubMed

73.

Wallace, E. M., Rizzi, J. P., Han, G., Wehn, P. M., Cao, Z., Du, X., et al. (2016). A small-molecule antagonist of HIF2alpha is efficacious in preclinical models of renal cell carcinoma. Cancer Research, 76(18), 5491–5500. https://doi.org/10.1158/0008-5472.CAN-16-0473.CrossRefPubMed

74.

Courtney, K. D., Infante, J. R., Lam, E. T., Figlin, R. A., Rini, B. I., Brugarolas, J., Zojwalla, N. J., Lowe, A. M., Wang, K., Wallace, E. M., Josey, J. A., & Choueiri, T. K. (2017). Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2α antagonist in patients with previously treated advanced clear cell renal cell carcinoma. Journal of Clinical Oncology, 36(9), 867–874. https://doi.org/10.1200/JCO.2017.74.2627.CrossRefPubMedPubMedCentral

75.

Tufton, N., Shapiro, L., Srirangalingam, U., Richards, P., Sahdev, A., Kumar, A. V., McAndrew, L., Martin, L., Berney, D., Monson, J., Chew, S. L., Waterhouse, M., Druce, M., Korbonits, M., Metcalfe, K., Drake, W. M., Storr, H. L., & Akker, S. A. (2017). Outcomes of annual surveillance imaging in an adult and paediatric cohort of succinate dehydrogenase B mutation carriers. Clin Endocrinol (Oxf), 86(2), 286–296. https://doi.org/10.1111/cen.13246.CrossRef

76.

Gimenez-Roqueplo, A.-P., Favier, J., Rustin, P., Rieubland, C., Crespin, M., Nau, V., Khau van Kien, P., Corvol, P., Plouin, P. F., Jeunemaitre, X., & COMETE Network. (2003). Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Research, 63(17), 5615–5621.PubMed

77.

Amar, L., Baudin, E., Burnichon, N., Peyrard, S., Silvera, S., Bertherat, J., et al. (2007). Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. Journal of Clinical Endocrinology and Metabolism, 92(10), 3822–3828. https://doi.org/10.1210/jc.2007-0709.CrossRefPubMed

78.

Neumann, H. H., Pawlu, C., Pęczkowska, M., et al. (2004). Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. Journal of the American Medical Association, 292(8), 943–951. https://doi.org/10.1001/jama.292.8.943.CrossRefPubMed

79.

Benn, D. E., Gimenez-Roqueplo, A. P., Reilly, J. R., Bertherat, J., Burgess, J., Byth, K., Croxson, M., Dahia, P. L., Elston, M., Gimm, O., Henley, D., Herman, P., Murday, V., Niccoli-Sire, P., Pasieka, J. L., Rohmer, V., Tucker, K., Jeunemaitre, X., Marsh, D. J., Plouin, P. F., & Robinson, B. G. (2006). Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. Journal of Clinical Endocrinology and Metabolism, 91(3), 827–836. https://doi.org/10.1210/jc.2005-1862.CrossRefPubMed

80.

Timmers, H. J. L. M., Kozupa, A., Eisenhofer, G., Raygada, M., Adams, K. T., Solis, D., et al. (2007). Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas. The Journal of Clinical Endocrinology & Metabolism, 92(3), 779–786. https://doi.org/10.1210/jc.2006-2315.CrossRef

81.

Eisenhofer, G., Pacak, K., Huynh, T.-T., Qin, N., Bratslavsky, G., Linehan, W. M., Mannelli, M., Friberg, P., Grebe, S. K., Timmers, H. J., Bornstein, S. R., & Lenders, J. W. (2010). Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. Endocrine-Related Cancer, 18(1), 97–111. https://doi.org/10.1677/ERC-10-0211.CrossRefPubMedPubMedCentral

82.

Eisenhofer, G., Goldstein, D. S., Sullivan, P., Csako, G., Brouwers, F. M., Lai, E. W., Adams, K. T., & Pacak, K. (2005). Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine. The Journal of Clinical Endocrinology & Metabolism, 90(4), 2068–2075. https://doi.org/10.1210/jc.2004-2025.CrossRef

83.

Eisenhofer, G., Lenders, J. W. M., Timmers, H., Mannelli, M., Grebe, S. K., Hofbauer, L. C., et al. (2011). Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clinical Chemistry, 57(3), 411–420. https://doi.org/10.1373/clinchem.2010.153320.CrossRefPubMedPubMedCentral

84.

Tufton, N., Sahdev, A., & Akker, S. A. (2017). Radiological surveillance screening in asymptomatic succinate dehydrogenase mutation carriers. Journal of the Endocrine Society, 1(7), 897–907. https://doi.org/10.1210/js.2017-00230.CrossRefPubMedPubMedCentral

Titel: Current management of succinate dehydrogenase–deficient gastrointestinal stromal tumors
verfasst von: Pushpa Neppala
Sudeep Banerjee
Paul T. Fanta
Mayra Yerba
Kevin A. Porras
Adam M. Burgoyne
Jason K. Sicklick
Publikationsdatum: 26.11.2019
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 3/2019
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-019-09818-0

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Current management of succinate dehydrogenase–deficient gastrointestinal stromal tumors

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2019

KISS1 in breast Cancer progression and autophagy

Exosomes as a storehouse of tissue remodeling proteases and mediators of cancer progression

Beyond the biomarker role: prostate-specific antigen (PSA) in the prostate cancer microenvironment

Functional disparities within the TIMP family in cancer: hints from molecular divergence

The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding

Specifically targeting cancer proliferation and metastasis processes: the development of matriptase inhibitors

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie